AIFM2 and glioblastoma: In malignant brain tumors, particularly glioblastoma and diffuse glioma, FSP1 expression is markedly elevated and consistently identified as a high-risk gene across multiple ferroptosis-based prognostic models, strongly implicating its role in poor clinical outcomes [93,94].